Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

Phase 2/3 Not yet recruiting 37 enrolled University Health Network, Toronto

NaSingle-groupOpen-labelTreatment

Summary

The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of semaglutide therapy in 37 KTR at risk of post-transplant diabetes mellitus (PTDM).

Timeline

Start: 2026-09-05
Primary completion: 2029-06-30
Completion: 2029-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Semaglutide	Peptide	2.4 mg	Subcutaneous

Indications

No indication recorded.